DARVON W/ ASA
LOE Approachingaspirin; propoxyphene hydrochloride
NDAORALCAPSULEPriority Review
Approved
Nov 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON W/ ASA is a combination analgesic containing propoxyphene hydrochloride and aspirin, indicated for mild to moderate pain relief. This oral capsule combines an opioid analgesic with a non-steroidal anti-inflammatory agent to provide adjunctive pain management.
LOE Approaching
This product is in late-stage decline with moderate competitive pressure (30), indicating a contracting team focused on managed decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DARVON W/ ASA offers limited career advancement opportunities given its approaching loss of exclusivity and minimal linked job openings. Roles focus on defending market share and managing decline rather than driving growth or innovation.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.